EDAP Reports Continued Strong Growth in Third Quarter 2014

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
EDAP Reports Continued Strong Growth in Third Quarter 2014

Highlights

  • Revenues increased 27% year-over-year to EUR 20.3 million (USD 27.4 million) for the first nine months of 2014
  • HIFU revenue increased 114% year-over-year during first nine months of 2014
  • Positive operating income, excluding FDA-related costs, for three and nine months ended September 30, 2014
  • Solid financial profile with cash position of EUR 11.1 million (USD 14.0 million)
  • Three Focal One Systems sold during third quarter, demonstrates robust OUS demand for next-generation HIFU device
  • Recent FDA guidance on Ablatherm HIFU PMA submission provides clear U.S. regulatory path and opportunity.

LYON, France, Nov. 20, 2014 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq: EDAP ), the global leader in therapeutic ultrasound, announced today financial results for the third quarter and nine months ended September 30, 2014 and provided an update on recent strategic and operational developments.

Marc Oczachowski, EDAP's Chief Executive Officer, stated, "We continue to make significant progress on several fronts in the second half of 2014. Of most note is the continued OUS adoption of our world class HIFU technology, which led revenue from this segment of our business to more than double in the first nine months of 2014 compared to the first nine months of 2013 with a total of ten systems sold, up from two in the year-ago period."

"The third quarter was particularly exciting, as we recognized revenue from three Focal One device sales. As reported in recent communication, these 3 devices were sold and installed in recognized and leading prostate cancer centers in France and Germany. This is a clear recognition of the high value of EDAP's broad range of HIFU devices and the increasing need of a complement to surgery, to address the changing prostate cancer patient population."

Mr. Oczachowski continued, "In the U.S., we recently reached an important milestone in our ongoing regulatory efforts with the receipt of a letter from the FDA. This letter provided specific recommendations for amendments to our Ablatherm-HIFU PMA that would make the application approvable. This comprehensive guidance reflects the extensive discussions we have had with the FDA since our Advisory Panel meeting. We are excited by the growth that our HIFU business has achieved to-date and the broader growth potential in the global urology market. In addition, we remain steadfastly committed to advancing the FDA approval process, and to bringing this therapeutic option to prostate cancer patients in the U.S."

Third Quarter 2014 Results

Total revenue for the third quarter 2014 was EUR 6.9 million (USD 9.0 million), a 24% year-over-year increase compared to EUR 5.6 million (USD 7.4 million) for the third quarter 2013. Total revenue included a EUR 0.5 million (USD 0.7 million) one-off revenue related to the licensing of a HIFU patent.

Total revenue for the HIFU division was EUR 2.9 million (USD 3.9 million) for the third quarter 2014, compared to EUR 1.2 (USD 1.7 million) for the same period last year. Results for the third quarter 2014 included the sale of three Focal One devices.

For the three months ended September 30, 2014, total revenue for the lithotripsy division was EUR 4.0 million (USD 5.4 million), compared to EUR 4.3 million (USD 5.8 million), during the year ago period. During the third quarter 2014, the Company recorded sales of seven lithotripsy machines, comprised of five Sonolith i-move devices, one Sonolith i-sys device, and one Sonolith Praktis. This compares to nine devices sold in the third quarter of 2013.

Gross profit for the third quarter 2014 was EUR 3.4 million (USD 4.4 million), compared to EUR 2.2 million (USD 3.0 million) for the year ago period. Gross profit margin on net sales was 45.2% in the third quarter of 2014, compared to 40.3% in the year ago period.

Operating expenses were EUR 3.1 million (USD 4.0 million) for the third quarter 2014, compared to EUR 2.6 million (USD 3.4 million) for the same period in 2013.

Operating income for the quarter was EUR 339,000 (USD 443,000), compared with an operating loss in the third quarter of 2013 of EUR 333,000 (USD 444,000).

Net income for the third quarter 2014 was EUR 6.6 million (USD 8.6 million), or EUR 0.26 per diluted share, as compared to a net loss for the third quarter 2013 of EUR 373,000 (USD 497,000), or EUR 0.02 per diluted share. Net income in the third quarter of 2014 included non-cash interest income of EUR 6.5 million to adjust the accounting fair value of outstanding warrants.

Results for the Nine Months Ended September 30, 2014

Total revenue for the first nine months of 2014 was EUR 20.3 million (USD 27.4 million), up 27.0% compared to EUR 16.0 million (USD 21.1 million) for the first nine months of 2013.

Gross profit for the period was EUR 8.8 million (USD 11.8 million), with gross profit margin on net sales of 41.7%, compared to 37.9% in the year ago period.

Operating loss for the first nine months of 2014 was EUR 707,000 (USD 954,000), an improvement of EUR 2.3 million over operating loss of EUR 3.0 million (USD 3.9 million) in the first nine months of 2013. Excluding FDA-related costs, operating income for the first nine months of 2014 was EUR 0.3 million (USD 0.4 million).

Net income for the nine months ended September 30, 2014 was EUR 2.1 million (USD 2.9 million), or EUR 0.09 per diluted share, as compared to net loss of EUR 4.5 million (USD 5.9 million), or EUR 0.22 per diluted share, in the same period in 2013. Net income in the 2014 period included non-cash interest income of EUR 3.0 million to adjust the accounting fair value of the outstanding warrants.

At September 30, 2014, cash and cash equivalents, including short-term treasury investments, were EUR 11.1 million (USD 14.0 million).

Conference Call

EDAP will hold a conference call on Thursday, November 20, 2014 at 8:30 a.m. EST to discuss the results. The dial-in numbers are 1-877-300-8521 for domestic callers and 1-412-317-6026 for international callers. The conference ID number for both is 10055617. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at www.edap-tms.com .

After the live event, the webcast will remain available on EDAP's website, www.edap-tms.com , through December 20, 2014. In addition, a dial-in replay of the call will be available until November 27, 2014. The replay dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for international callers. Please use event passcode 10055617.

About EDAP TMS SA

EDAP TMS SA markets today Ablatherm ® for high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. following submission of the Pre-Market Approval Application in February 2013 after the completion of a multi-center U.S. Phase II/III clinical trial under an Investigational Device Exemption (IDE) granted by the FDA. In March 2013, the Company introduced a new innovative HIFU device, the Focal One ® dedicated to focal therapy of prostate cancer. Focal One ® is CE marked but is not FDA approved. The Company also develops its HIFU technology for the potential treatment of certain other types of tumors. EDAP TMS SA also produces and commercializes medical equipment (the Sonolith ® range) for treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com , and http://www.hifu-planet.com .

Forward-Looking Statements

In addition to historical information, this press release may contain forward-looking statements. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others the uncertainties of the U.S. FDA approval process, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy device. Factors that may cause such a difference also may include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F. Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or marketed in the United States.

EDAP TMS S.A.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(Amounts in thousands of Euros and U.S. Dollars, except per share data)
         
  Three Months Ended : Three Months Ended :
  September 30,
2014
September 30,
2013
September 30,
2014
September 30,
2013
  Euros Euros $US $US
Sales of goods  4,192  3,271  5,474  4,363
Net Sales of RPP and Leases  824  920  1,075  1,226
Sales of spare parts and services  1,384  1,371  1,807  1,829
TOTAL NET SALES  6,400  5,562  8,356  7,418
Other revenues  511  1  667  2
TOTAL REVENUES  6,911  5,563  9,023  7,420
Cost of goods  (2,163)  (1,938)  (2,825)  (2,584)
Cost of RPP and Leases  (442)  (514)  (577)  (686)
Cost of spare parts & services  (899)  (870)  (1,174)  (1,161)
Cost of sales  (3,505)  (3,322)  (4,576)  (4,431)
         
GROSS PROFIT  3,406  2,241  4,447  2,989
Research & development expenses  (714)  (447)  (932)  (596)
Marketing & Sales expenses  (1,458)  (1,302)  (1,903)  (1,737)
G & A expenses  (895)  (825)  (1,169)  (1,100)
Total operating expenses  (3,067)  (2,574)  (4,004)  (3,432)
         
OPERATING PROFIT (LOSS)  339  (333)  443  (444)
Interest (expense) income, net  6,484  373  8,466  498
Currency exchange gains (loss), net  (245)  (385)  (320)  (514)
Other income (loss), net  (2)  3  (2)  3
         
INCOME (LOSS) BEFORE TAXES AND MINORITY INTEREST  6,577  (343)  8,587  (457)
Income tax (expense) credit  (26)  (30)  (34)  (40)
         
NET INCOME (LOSS)  6,551  (373)  8,554  (497)
Earning per share – Basic  0.26  (0.02)  0.34  (0.02)
         
Average number of shares used in computation of Basic EPS 24,859,267 21,789,670 24,859,267 21,789,670
         
Earning per share – Diluted  0.26  (0.02)  0.33  (0.02)
         
Average number of shares used in computation of Diluted EPS 25,623,929 21,789,670 25,623,929 21,789,670
         
NOTE:  Translated for convenience of the reader to U.S. dollars at the 2014 average three months noon buying rate of 1 Euro = 1.3057 USD, and 2013 average three months noon buying rate of 1 Euro = 1.3337 USD.
         
         
EDAP TMS S.A.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
(Amounts in thousands of Euros and U.S. Dollars, except per share data)
         
  Nine Months Ended : Nine Months Ended :
  September 30,
2014
September 30,
2013
September 30,
2014
September 30,
2013
  Euros Euros $US $US
Sales of goods  12,948  9,216  17,474  12,150
Net Sales of RPP and Leases  2,846  2,889  3,841  3,809
Sales of spare parts and services  4,002  3,883  5,401  5,120
TOTAL NET SALES  19,797  15,988  26,716  21,079
Other revenues  511  4  690  5
TOTAL REVENUES  20,308  15,993  27,406  21,085
Cost of goods  (7,322)  (5,550)  (9,881)  (7,317)
Cost of RPP and Leases  (1,583)  (1,636)  (2,137)  (2,157)
Cost of spare parts & services  (2,629)  (2,740)  (3,548)  (3,613)
Cost of sales  (11,535)  (9,926)  (15,566)  (13,087)
         
GROSS PROFIT  8,773  6,066  11,840  7,998
Research & development expenses  (2,332)  (2,025)  (3,147)  (2,670)
Marketing & Sales expenses  (4,521)  (4,396)  (6,102)  (5,795)
G & A expenses  (2,627)  (2,627)  (3,545)  (3,463)
Total operating expenses  (9,480)  (9,048)  (12,793)  (11,929)
         
OPERATING PROFIT (LOSS)  (707)  (2,982)  (954)  (3,931)
Interest (expense) income, net  2,930  (239)  3,954  (315)
Currency exchange gains (loss), net  (29)  (1,142)  (39)  (1,506)
Other income (loss), net  (6)  3  (8)  4
         
INCOME (LOSS) BEFORE TAXES AND MINORITY INTEREST  2,188  (4,360)  2,953  (5,748)
Income tax (expense) credit  (62)  (91)  (84)  (120)
         
NET INCOME (LOSS)  2,126  (4,451)  2,869  (5,869)
Earning per share – Basic  0.09  (0.22)  0.12  (0.29)
         
Average number of shares used in computation of Basic EPS 23,157,314 20,169,756 23,157,314 20,169,756
         
Earning per share – Diluted  0.08  (0.22)  0.11  (0.29)
         
Average number of shares used in computation of Diluted EPS 25,296,513 20,169,756 25,296,513 20,169,756
         
NOTE:  Translated for convenience of the reader to U.S. dollars at the 2014 average nine months noon buying rate of 1 Euro = 1.3495 USD, and 2013 average nine months noon buying rate of 1 Euro = 1.3184 USD.
 
 
EDAP TMS S.A.
CONSOLIDATED BALANCE SHEETS HIGHLIGHTS (UNAUDITED)
(Amounts in thousands of Euros and U.S. Dollars)
         
  Sept. 30,
2014
Jun. 30,
2014
Sept. 30,
2014
Jun. 30,
2014
  Euros Euros $US $US
         
Cash, cash equivalents and short term investments  11,055 12,799 13,960 17,520
Total current assets 27,578 27,473 34,825 37,608
Total current liabilities 11,622 11,484 14,676 15,721
Shareholders' Equity  17,778 11,283 22,450 15,445
         
NOTE:  Translated for convenience of the reader to U.S. dollars at the noon buying rate of 1 Euro = 1.2628 USD, on September 30, 2014 and at the noon buying rate of 1 Euro = 1.3689 USD, on June, 2014.
 
 
EDAP TMS S.A.
CONDENSED STATEMENTS OF OPERATIONS BY DIVISION
NINE MONTHS ENDED SEPTEMBER 30, 2014
(Amounts in thousands of Euros)
                 
                 
  HIFU
Division
  UDS
Division
  FDA
Trials

Corporate
  Total After
Consolidation
 
                 
Sales of goods 5,053   7,895       12,948  
Sales of RPPs & Leases 1,536   1,310       2,846  
Sales of spare parts & services 596   3,406       4,002  
TOTAL NET SALES 7,186   12,611       19,797  
                 
Other revenues 511   --       511  
                 
TOTAL REVENUES 7,697   12,611       20,308  
                 
GROSS PROFIT 4,540 56% 4,233 34%      8,773 42%
                 
Research & Development  (751)    (582)    (999)    (2,332)  
Total SG&A plus depreciation  (1,915)    (4,133)      (1,100)  (7,148)  
                 
OPERATING PROFIT (LOSS)  1,875    (482)    (999)  (1,100)  (707)  

Blandine Confort Investor Relations / Legal Affairs EDAP TMS SA +33 4 72 15 31 72 Investors: Lee Roth The Ruth Group 646-536-7012

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Adecco Finds AI Value Depends on Better Work Redesign

Updated Category News Views 0

A shiny AI license is not a productivity strategy, and Adecco's latest workforce survey puts some hard numbers behind that irritation. The company surveyed 40,500 workers in 36 countries for its seventh Global Workforce of the Future report, released November 19, 2026. Its central finding is disarmingly sensible: AI produces more when companies rebuild the work around it...

Continue Reading
Nightguards and TMJ Appliances Require Different Calls

Updated Category News Views 126

Two clear plastic devices can invite a costly wrong turn. Dr. Terrance O’Keefe’s explanation, published Nov. 18, 2026, draws a line that patients too often blur: a nightguard protects teeth from grinding, while a TMJ appliance is meant to address joint and muscle strain tied to temporomandibular disorders. They may look alike sitting in a case. Their jobs are not...

Continue Reading
MIND Takes Its Copilot Security Bet Across Microsoft 365

Updated Category News Views 81

Copilot’s promise gets a lot less charming the minute confidential files start wandering around unchecked. That is the knot MIND is trying to untie with its expanded, generally available integrations across Microsoft Copilot, Microsoft 365, Purview, Teams, SharePoint, OneDrive, Edge and Exchange. The Seattle data-loss-prevention company announced the collaboration on...

Continue Reading
HiTHIUM's 8-Hour Storage Pitch Faces Real Grid Tests

Updated Category News Views 89

Eight hours of stored electricity is where the sales brochure meets the ugly parts of the grid. HiTHIUM arrived at RE+ 2026 in Las Vegas, held November 17 through 19, with a broad storage pitch: systems ranging from two to eight hours, lithium-ion and sodium-ion chemistry, plus the software and validation work needed to make a battery plant behave when the local grid gets...

Continue Reading
LevelTen Takes Its Clean-Power Market Model to India

Updated Category News Views 61

India's power market is not a tidy spreadsheet, thankfully. It is a vast, fast-growing grid where data centres, factories and climate exposure are all colliding with a generation mix still dominated by coal. That is why LevelTen Energy's move into Asia-Pacific deserves more than the usual clean-tech applause line. Beginning with a 500 MW clean-energy request for proposals...

Continue Reading
Travelzoo Turns Thanksgiving Delays Into Member Value

Updated Category News Views 95

Airport gridlock is a miserable place to make a membership pitch, yet Travelzoo has found a pretty shrewd angle for it. On November 18, the company said nearly 20 million travelers will move through airports during the upcoming Thanksgiving holiday, when cancellations and delays can turn an ordinary trip into a long, fluorescent-lit slog. Its offer: qualifying Club...

Continue Reading
Tactical Tomahawk Motor Deal Puts Propulsion in Focus

Updated Category News Views 288

A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...

Continue Reading
Thanksgiving Dog Safety Is a Pet Care Reality Check

Updated Category News Views 94

A crowded Thanksgiving kitchen can turn a well-behaved dog into a scavenger with lousy odds. Camp Bow Wow’s holiday guidance is not pretending the meal itself is the problem; the trouble is that a house full of distracted people, rich food and unsecured trash creates a pile of easy mistakes. For pet owners, that is a fair reminder. For anybody watching the pet-care...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 153

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
LG Channels UAE Push Tests the Free Streaming Model

Updated Category News Views 137

A television's idle screen is turning into contested real estate in the UAE. LG Channels is adding programming from Rakuten TV, Stingray and Red Bull TV to its free, ad-supported service, and that matters for more than somebody hunting a movie after dinner. This is a practical push to make webOS-powered screens more useful, more frequently used and, eventually, more...

Continue Reading
on>

Top 5 Most Recently Viewed Articles

Exploring the Trading Landscape for Bitdeer Technologies

Updated Category News Views 99

Whales Are Bullish on Bitdeer Technologies Large investors, often referred to as whales, have shown a strong bullish sentiment towards Bitdeer Technologies. Recent observations from the options trading history reveal a total of eight significant trades in this period. Examining the nature of these trades indicates that approximately 62% were made with optimistic outlooks,...

Continue Reading
Successful Rafi's Amigos Golf Outing Raises Funds for JROTC

Updated Category News Views 188

Successful Fundraising at Rafi's Amigos Golf Outing On a recent day dedicated to supporting local youth, the Rafi's Amigos Golf Outing took place at Beavercreek Golf Club. Despite early rain, the weather brightened, allowing golfers and supporters to enjoy a seamless day on the course. With 116 participants, this year's event was recognized as a remarkable achievement,...

Continue Reading
Trinity Biotech Launches Innovative CGM Technology in India

Updated Category News Views 138

Trinity Biotech Prepares for CGM Launch in India Trinity Biotech plc (NASDAQ:TRIB), based in Dublin, is ready to make a notable stride in diabetes management with the launch of its advanced Continuous Glucose Monitoring (CGM) technology in India. The company has revealed plans for a crucial in-country study aimed at collecting feedback from diabetes patients and...

Continue Reading
Significant Market Growth for Fiberglass Fabrics Expected Soon

Updated Category News Views 259

Fiberglass Fabrics Market Growth Forecast A new market report reveals that the global fiberglass fabrics market is poised for substantial growth, projected to reach an increase of USD 2.83 billion between 2024 and 2028. This impressive expansion is expected to occur at a compound annual growth rate (CAGR) of 7.5% over the forecast period. The driving forces behind this...

Continue Reading
Earnings Insights for Hess Midstream: Key Metrics to Consider

Updated Category News Views 206

Anticipating Hess Midstream's Earnings Results Hess Midstream (NYSE:HESM) is gearing up to release its quarterly earnings report soon, poised to share vital insights that could impact investor sentiment. As the anticipation builds, understanding what to expect is crucial for current and prospective investors alike. Projected Earnings and Market Expectations Analysts are...

Continue Reading